MRG003 + pucotenlimab + cisplatin

MRG003 + pucotenlimab + cisplatin is a combination therapy under clinical investigation for the treatment of locally advanced or metastatic solid tumors, particularly EGFR-positive head and neck squamous cell carcinoma (HNSCC) and nasopharyngeal carcinoma. - **MRG003** is an antibody-drug conjugate (ADC) targeting the epidermal growth factor receptor (EGFR), designed to deliver cytotoxic agents directly to EGFR-expressing tumor cells, thereby inhibiting their growth and survival. - **Pucotenlimab** (HX008, brand name Puyouheng) is a recombinant humanized IgG4 monoclonal antibody that acts as a programmed death 1 (PD-1) immune checkpoint inhibitor. It blocks PD-1 from interacting with its ligands PD-L1 and PD-L2, restoring T-cell mediated antitumor immunity[6][9]. - **Cisplatin** is a well-established platinum-based chemotherapy agent that induces DNA crosslinking and apoptosis in rapidly dividing cancer cells. This combination leverages targeted cytotoxicity via EGFR inhibition, immune checkpoint blockade to enhance antitumor immunity, and broad cytotoxic effects from chemotherapy. Early-phase studies have shown promising efficacy in patients with HNSCC or nasopharyngeal carcinoma who are eligible for resection or have failed prior therapies[1][3][8].

Brand names

Puyouheng

Other names

MRG003 + HX008 + cisplatinMRG003 Injection Combined With Pucotenlimab Injection + Cisplatin Injection